Sugi Predict

Sugi Predict / Compounds / SCHEMBL21997258

SCHEMBL21997258

SCHEMBL21997258

C=CCCC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ GPR119 Q8TDV5 7/20 0.47
▸ RECQL P46063 1/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ FAAH O00519 1/20 0.46
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ NR1H2 P55055 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7375661 0.87 HPGD (0.51) HPGDKDM4EPKMGPR119RECQL
SCHEMBL7375656 0.87 HPGD (0.51) HPGDKDM4EPKMGPR119RECQL
SCHEMBL7375659 0.87 HPGD (0.51) HPGDKDM4EPKMGPR119RECQL
SCHEMBL23509491 0.86 NR1H2 (0.51) HPGDKDM4EPKMGPR119RECQL
SCHEMBL1576006 0.86 HPGD (0.50) HPGDKDM4EPKMGPR119RECQL
SCHEMBL1854557 0.86 HPGD (0.50) HPGDKDM4EPKMGPR119RECQL
SCHEMBL12934479 0.85 MEN1 (0.49) HPGDEPHX1NR1H2
SCHEMBL25833021 0.85 FAAH (0.47) HPGDKDM4EPKMGPR119FAAH
SCHEMBL445419 0.84 HPGD (0.54) HPGDKDM4EPKMGPR119RECQL
SCHEMBL31303434 0.83 GPR119 (0.46) HPGDKDM4EPKMGPR119RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12583818-B2 Compound, preparation method thereof, and use thereof DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2026-03-24 — — US disclosed
EP-4688779-A2 NOVEL COMPOUNDS AND USES THEREOF Acelink Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
EP-4680343-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-21 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
WO-2025026392-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2025-02-06 — — WO disclosed
EP-4065553-B1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) 2025-01-29 — — EP disclosed
WO-2024211244-A2 NOVEL COMPOUNDS AND USES THEREOF ACELINK THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
WO-2024192415-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-09-19 — — WO disclosed
EP-4065553-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2022-10-05 — — EP disclosed
CN-114981241-A Novel compound, preparation method and application thereof 大邱庆北尖端医疗产业振兴财团 2022-08-30 — — CN disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2021145729-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2021-07-22 — — WO disclosed
WO-2021145729-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2021-07-22 — — WO disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583818-B2 Compound, preparation method thereof, and use thereof TYRO3, TH, SRMS HPGD 3331/4885KDM4E 2818/4885PKM 4091/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HPGD 3843/4885KDM4E 190/4885PKM 1372/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HPGD 3843/4885KDM4E 190/4885PKM 1372/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HPGD 3843/4885KDM4E 190/4885PKM 1372/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HPGD 3843/4885KDM4E 190/4885PKM 1372/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HPGD 3843/4885KDM4E 190/4885PKM 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.